296 related articles for article (PubMed ID: 17720067)
21. Re: Prostaglandin E(2) inhibition and aqueous concentration of ketorolac 0.4% and nepafenac 0.1% in patients undergoing phacoemulsification.
Walters T
Am J Ophthalmol; 2007 Dec; 144(6):978-9; author reply 979-80. PubMed ID: 18036883
[No Abstract] [Full Text] [Related]
22. Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor.
Miyake K; Ogawa T; Tajika T; Gow JA; McNamara TR
J Ocul Pharmacol Ther; 2008 Dec; 24(6):573-8. PubMed ID: 19049295
[TBL] [Abstract][Full Text] [Related]
23. REDUCTION OF VITREOUS PROSTAGLANDIN E2 LEVELS AFTER TOPICAL ADMINISTRATION OF INDOMETHACIN 0.5%, BROMFENAC 0.09%, AND NEPAFENAC 0.1.
Russo A; Morescalchi F; Vezzoli S; Bernini M; Turano R; Costagliola C; De Ferrari F; Semeraro F
Retina; 2016 Jun; 36(6):1227-31. PubMed ID: 26562569
[TBL] [Abstract][Full Text] [Related]
24. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial.
Duong HV; Westfield KC; Chalkley TH
J Cataract Refract Surg; 2007 Nov; 33(11):1925-9. PubMed ID: 17964399
[TBL] [Abstract][Full Text] [Related]
25. Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK).
Durrie DS; Kennard MG; Boghossian AJ
Adv Ther; 2007; 24(6):1278-85. PubMed ID: 18165210
[TBL] [Abstract][Full Text] [Related]
26. VITREOUS PROSTAGLANDIN E2 CHANGES AFTER TOPICAL ADMINISTRATION OF DICLOFENAC 0.1%, INDOMETHACIN 0.5%, NEPAFENAC 0.3%, AND BROMFENAC 0.09.
Pastore MR; De Giacinto C; Cirigliano G; D'Aloisio R; Addobbati R; Agostinis C; Radillo O; Di Martino G; Di Nicola M; Cecchini P; Tognetto D
Retina; 2020 Sep; 40(9):1838-1845. PubMed ID: 31800462
[TBL] [Abstract][Full Text] [Related]
27. Topical NSAIDs effect on corneal sensitivity.
Singer DD; Kennedy J; Wittpenn JR
Cornea; 2015 May; 34(5):541-3. PubMed ID: 25826326
[TBL] [Abstract][Full Text] [Related]
28. Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation.
Trattler W; McDonald M
Cornea; 2007 Jul; 26(6):665-9. PubMed ID: 17592313
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of non-steroidal anti-inflammatory drugs on mitochondrial dysfunction during oxidative stress.
Lal N; Kumar J; Erdahl WE; Pfeiffer DR; Gadd ME; Graff G; Yanni JM
Arch Biochem Biophys; 2009 Oct; 490(1):1-8. PubMed ID: 19810214
[TBL] [Abstract][Full Text] [Related]
30. Bromfenac ophthalmic solution 0.09 %: human aqueous humor concentration detected by high-performance liquid chromatography.
Macrì A; Vagge A; Salis A; Fucile C; Marini V; Martelli A; Giuffrida S; Iester M; Damonte G; Mattioli F
Int Ophthalmol; 2017 Apr; 37(2):417-421. PubMed ID: 27324371
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification.
Almeida DR; Khan Z; Xing L; Bakar SN; Rahim K; Urton T; El-Defrawy SR
J Cataract Refract Surg; 2012 Sep; 38(9):1537-43. PubMed ID: 22795976
[TBL] [Abstract][Full Text] [Related]
32. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery.
Lane SS; Modi SS; Lehmann RP; Holland EJ
J Cataract Refract Surg; 2007 Jan; 33(1):53-8. PubMed ID: 17189793
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic comparisons of bromfenac in DuraSite and Xibrom.
Si EC; Bowman LM; Hosseini K
J Ocul Pharmacol Ther; 2011 Feb; 27(1):61-6. PubMed ID: 21332395
[TBL] [Abstract][Full Text] [Related]
34. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy.
Gamache DA; Graff G; Brady MT; Spellman JM; Yanni JM
Inflammation; 2000 Aug; 24(4):357-70. PubMed ID: 10850857
[TBL] [Abstract][Full Text] [Related]
35. Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Retinal Diseases.
Rodrigues EB; Farah ME; Bottós JM; Bom Aggio F
Dev Ophthalmol; 2016; 55():212-20. PubMed ID: 26502088
[TBL] [Abstract][Full Text] [Related]
36. Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits.
Shafiee A; Bowman LM; Hou E; Hosseini K
J Ocul Pharmacol Ther; 2013 Nov; 29(9):812-6. PubMed ID: 23992042
[TBL] [Abstract][Full Text] [Related]
37. The Effects of Two Non-Steroidal Anti-Inflammatory Drugs, Bromfenac 0.1% and Ketorolac 0.45%, on Cataract Surgery.
Jung JW; Chung BH; Kim EK; Seo KY; Kim TI
Yonsei Med J; 2015 Nov; 56(6):1671-7. PubMed ID: 26446653
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the efficacy and patients' tolerability of Nepafenac and Ketorolac in the treatment of ocular inflammation following cataract surgery: A meta-analysis of randomized controlled trials.
Zhao X; Xia S; Wang E; Chen Y
PLoS One; 2017; 12(3):e0173254. PubMed ID: 28253334
[TBL] [Abstract][Full Text] [Related]
39. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits.
Baklayan GA; Patterson HM; Song CK; Gow JA; McNamara TR
J Ocul Pharmacol Ther; 2008 Aug; 24(4):392-8. PubMed ID: 18665811
[TBL] [Abstract][Full Text] [Related]
40. Topical nepafenac inhibits ocular neovascularization.
Takahashi K; Saishin Y; Saishin Y; Mori K; Ando A; Yamamoto S; Oshima Y; Nambu H; Melia MB; Bingaman DP; Campochiaro PA
Invest Ophthalmol Vis Sci; 2003 Jan; 44(1):409-15. PubMed ID: 12506103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
